Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with ad... Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with advanced solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod. Show more
LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (βMereoβ or the βCompanyβ), a clinical-stage biopharmaceutical company focused on rare diseases, today...
Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.3544 | 10.8048780488 | 3.28 | 3.88 | 3.11 | 1114654 | 3.57241379 | CS |
4 | 0.0744 | 2.08988764045 | 3.56 | 3.94 | 3.11 | 990753 | 3.54904269 | CS |
12 | -0.7656 | -17.4 | 4.4 | 4.72 | 3.11 | 804406 | 3.79843585 | CS |
26 | 0.1444 | 4.13753581662 | 3.49 | 5.02 | 3.11 | 854482 | 3.98519685 | CS |
52 | 1.3244 | 57.3333333333 | 2.31 | 5.02 | 2.23 | 1134239 | 3.62789366 | CS |
156 | 1.9944 | 121.609756098 | 1.64 | 5.02 | 0.301 | 1417814 | 1.89966054 | CS |
260 | 1.1944 | 48.9508196721 | 2.44 | 5.02 | 0.301 | 1269052 | 2.32590556 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.